Virpax Pharmaceuticals, Inc. Overview
Pro stress-test →Virpax Pharmaceuticals Inc. (Nasdaq: VRPX) is a specialty pharmaceutical company focused on pioneering advanced healthcare solutions with Probudur, its flagship product leveraging proprietary liposomal encapsulation. The company is dedicated to developing the next generation of non-opioid pain products to help patients manage pain. With a focus on optimizing non-addictive medications, the company's drug delivery platforms target unmet global needs in markets such as post-operative pain, severe pain, post-cancer pain, and rare pediatric epilepsy, including orphan diseases like Lennox-Gastaut Syndrome and Dravet Syndrome.
Strategic Profile
Pro stress-test →Virpax is a preclinical stage biopharmaceutical company leveraging proprietary drug delivery technologies across multiple indications. The company is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms: Probudur, a single injection liposomal bupivacaine formulation being developed to manage post-operative pain, and Envelta, an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Additional product candidates include PES200, being developed to manage post-traumatic stress disorder (PTSD), and NobrXiol, being developed for nasal delivery of pharmaceutical-grade cannabidiol (CBD) for management of rare pediatric epilepsy.
Competitive Landscape
Pro stress-test →Virpax is developing branded, non-addictive pain management product candidates using proprietary technologies to optimize and target drug delivery, initially seeking FDA approval for two prescription drug candidates employing two different patented drug delivery platforms. The company competes in the non-opioid pain management space alongside larger pharma companies (e.g., Pacira Pharmaceuticals for post-operative pain), specialized biotech focusing on pain/CNS, and emerging drug delivery platforms. Virpax's differentiation lies in its proprietary liposomal encapsulation and molecular envelope technology targeting sustained or intranasal delivery.
Industry Context
Virpax Pharmaceuticals, Inc. operates in Non-opioid pain management drug delivery.
Key facts
Founded: 2016 · Headquarters: Berwyn, PA, US · Employees: 2 · Market cap: $124M